secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001601830-24-000035
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion appoints Najat Khan as Chief R&D and Commercial Officer, joins board
------------------------------------------------------------------------------

- Dr. Khan appointed Chief R&D Officer and Chief Commercial Officer; also elected Class II Director with term through 2026.
- Compensation: base salary $570k, target bonus 50% of base, sign-on bonus $500k, initial equity grant $8M (half RSUs, half options, 4-yr vest).
- Previously Chief Data Science Officer at J&J; will lead R&D and build commercial capabilities at Recursion.
- Board expanded from 8 to 9 members; no related-party transactions requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/0001601830-24-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/rxrx-20240415.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer